MDT

88.62

+0.97%↑

VEEV

282.02

-0.6%↓

A

121.9

+2.49%↑

WBA

11.5

0%↓

HQY

102.96

+1.44%↑

MDT

88.62

+0.97%↑

VEEV

282.02

-0.6%↓

A

121.9

+2.49%↑

WBA

11.5

0%↓

HQY

102.96

+1.44%↑

MDT

88.62

+0.97%↑

VEEV

282.02

-0.6%↓

A

121.9

+2.49%↑

WBA

11.5

0%↓

HQY

102.96

+1.44%↑

MDT

88.62

+0.97%↑

VEEV

282.02

-0.6%↓

A

121.9

+2.49%↑

WBA

11.5

0%↓

HQY

102.96

+1.44%↑

MDT

88.62

+0.97%↑

VEEV

282.02

-0.6%↓

A

121.9

+2.49%↑

WBA

11.5

0%↓

HQY

102.96

+1.44%↑

Search

Aurinia Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

7.66 3.23

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.35

Max

7.67

Pagrindiniai rodikliai

By Trading Economics

Pajamos

22M

23M

Pardavimai

2.6M

62M

P/E

Sektoriaus vid.

31.37

40.527

Pelnas, tenkantis vienai akcijai

0.16

Pelno marža

37.371

Darbuotojai

130

EBITDA

15M

22M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+30.52% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

16M

1.1B

Ankstesnė atidarymo kaina

4.43

Ankstesnė uždarymo kaina

7.66

Naujienos nuotaikos

By Acuity

77%

23%

348 / 375 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-07 15:29; UTC

Pagrindinės rinkos jėgos

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

2025-07-07 23:44; UTC

Rinkos pokalbiai

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

2025-07-07 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-07 23:41; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

2025-07-07 23:19; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-07 23:19; UTC

Rinkos pokalbiai

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

2025-07-07 22:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-07 22:20; UTC

Rinkos pokalbiai

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

2025-07-07 21:34; UTC

Įsigijimai, susijungimai, perėmimai

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

2025-07-07 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-07 20:45; UTC

Įsigijimai, susijungimai, perėmimai

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

2025-07-07 20:16; UTC

Rinkos pokalbiai

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

2025-07-07 19:37; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

2025-07-07 19:12; UTC

Rinkos pokalbiai

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

2025-07-07 18:33; UTC

Rinkos pokalbiai

Gold Flat as Investors Assess Market Direction -- Market Talk

2025-07-07 18:27; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-07 16:53; UTC

Uždarbis

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

2025-07-07 16:30; UTC

Rinkos pokalbiai

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

2025-07-07 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-07 16:05; UTC

Įsigijimai, susijungimai, perėmimai

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

2025-07-07 15:41; UTC

Rinkos pokalbiai

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

2025-07-07 15:41; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-07 15:40; UTC

Rinkos pokalbiai

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

2025-07-07 15:30; UTC

Rinkos pokalbiai

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

2025-07-07 15:18; UTC

Rinkos pokalbiai

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

2025-07-07 15:14; UTC

Įsigijimai, susijungimai, perėmimai

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

2025-07-07 15:00; UTC

Įsigijimai, susijungimai, perėmimai

GSK Completes Acquisition of Efimosfermin

2025-07-07 14:52; UTC

Rinkos pokalbiai

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

2025-07-07 14:51; UTC

Rinkos pokalbiai

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

2025-07-07 14:45; UTC

Rinkos pokalbiai

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

30.52% į viršų

12 mėnesių prognozė

Vidutinis 9.75 USD  30.52%

Aukščiausias 11 USD

Žemiausias 8 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.1 / 8.21Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

348 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.